Collectively, our results imply that the decrease of NAV3 expression levels in GBM likely stems from a large tumor core containing necrotic regions, exhibiting low NAV3, rather than being indicative of a tumor suppressor role of NAV3 in glioma cells. The gene discussed is NAV3; the disease is central nervous system cancer.